EVIDENCE AT A GLANCE

ReadyOS Measurement Validation

Completed 90-second accuracy testing and comparative HRV evaluation—without the jargon.

Trust begins with the measurement. ReadyOS is built to give clinicians a practical, repeatable view of physiological readiness. Its 90-second scan is not presented merely as a proposed technology: NeuPT Technologies reports completed engineering accuracy validation and a completed comparison with an established ECG-based HRV assessment.

Completed ReadyOS measurement evaluations

Evaluation	Status	What this supports
90-second Standard Scan accuracy	COMPLETED	The engineering team has validated measurement accuracy for the tested Standard Scan implementation.
ReadyOS vs. NeuPT HRV metrics	COMPLETED	Comparative measurement validation against the established ECG-based NeuPT HRV system involved engineering and an independent researcher.

These statements reflect completed technical activities confirmed by NeuPT Technologies. They do **not** imply that every proprietary score, sensor configuration, software revision, or clinical population has received the same evaluation.

Why the reference matters

NeuPT HRV is the earlier ECG-based assessment system that helped establish the clinic workflow from which ReadyOS evolved. Comparison with its established HRV metrics provides a meaningful technical bridge between the predecessor measurement platform and ReadyOS. The historical 1996 ESC/NASPE guidelines supply the broader HRV measurement framework; they are not an endorsement or certification of ReadyOS.

What “validated” means here

- **Accuracy:** testing of whether the 90-second Standard Scan measures the physiological quantities evaluated by the engineering team with acceptable performance.
- **Comparative agreement:** evaluation of ReadyOS measurements against corresponding measurements from the NeuPT HRV reference assessment.
- **Clinical outcomes:** a separate question—whether proprietary readiness guidance predicts outcomes or improves care—which is not established by measurement agreement alone.

© 2026 NeuPT Technologies • Public edition 1.0 • October 2026

Clear evidence, appropriately scoped

NeuPT Technologies has not included metric-by-metric observed error, agreement coefficients, sample sizes, or the independent evaluator's signed conclusions in this concise public summary. No numeric performance statistics should be inferred from engineering acceptance targets or from earlier NeuPT HRV studies. Specific quantitative claims should be tied to the tested software build, sensor, protocol, metric, and participant population.

Additional technical documentation may be requested directly from NeuPT Technologies for appropriate diligence. This short public summary is intended to explain what work has been completed—not to replace its underlying test records.

Separate research on the predecessor system

A 2023 preprint by A. Christopher Wikman explored the NeuPT HRV system in a small seven-participant study using 300-heartbeat recordings. That research is part of the company's historical scientific background. It was not a ReadyOS 90-second validation study and is distinct from the completed ReadyOS engineering and independent comparative evaluation.

90-SECOND MEASUREMENT VALIDATION: COMPLETED. CLINICAL OUTCOME RESEARCH: A DISTINCT NEXT QUESTION.

Public evidence status: October 19, 2026. No diagnostic or disease-prediction claim is made by this summary.

Selected scientific references

1. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Circulation. 1996;93(5):1043–1065. https://pubmed.ncbi.nlm.nih.gov/8598068/

2. Wikman AC. The NeuPT HRV Diagnostic System has Clinical Utility in Measuring Acute Responses to Integrative Therapies. Preprint, 2023. https://doi.org/10.31219/osf.io/69jc2